NICE CG189 provides evidence-based guidance on identifying, assessing, and managing obesity in UK clinical practice, improving patient outcomes and reducing weight-related complications.

Dupilumab guidance for moderate-to-severe atopic dermatitis in UK patients; clarifies NHS funding eligibility and treatment criteria for clinicians.

Mepolizumab reduces severe asthma attacks in patients with high eosinophil counts, offering NHS-approved treatment when standard therapies fail.

NICE NG117 provides evidence-based guidance for diagnosing and managing non-cystic fibrosis bronchiectasis, improving UK clinical outcomes and standardising care.

NICE NG202 provides evidence-based guidance for diagnosing and managing sleep apnoea in UK patients, improving outcomes and reducing untreated disease complications.

NICE NG163 guides UK clinicians on diagnosing and managing idiopathic pulmonary fibrosis, improving patient outcomes through standardised evidence-based care pathways.

TA773 approves Empagliflozin for heart failure with reduced ejection fraction, offering clinicians an effective treatment option to improve patient outcomes and reduce…

TA631 evaluates TAVI versus surgical replacement for aortic valve disease, guiding UK clinicians on cost-effective treatment selection for patients.

NICE NG128 provides evidence-based guidance on diagnosing strokes and TIAs and initial management, essential for UK clinicians to optimize patient outcomes.

NICE CG147 provides evidence-based guidance on diagnosing and managing peripheral arterial disease, helping UK clinicians improve patient outcomes and reduce cardiovascular complications.